Antibody Drug Conjugates (ADC)

Integrated antibody‑drug conjugate (ADC) development and manufacturing services support programs from early clinical stages through commercial production. Capabilities span antibody intermediates, linker‑payload manufacturing, and conjugation, enabling coordinated control of complex, high‑potency processes across the ADC lifecycle.

Advanced analytical development, release testing, and stability programs support robust product understanding and quality assurance. Tools include chromatography, electrophoresis, spectroscopy, bioassays, and characterization methods designed to monitor critical quality attributes such as drug‑to‑antibody ratio and conjugation consistency. Scalable manufacturing options support a wide range of batch sizes using single‑use and stainless‑steel technologies in highly engineered containment environments.

Dedicated facilities and experienced scientific teams enable seamless transitions from development through GMP clinical and commercial manufacturing. Together, these integrated capabilities help mitigate technical and operational risk, support regulatory readiness, and provide a reliable pathway for advancing ADC programs from early milestones to global market supply.